Bufexamac

Bufexamac is an NSAID and inhibitor of the class IIb histone deacetylases HDAC6 and HDAC10. It inhibits the production of IFN-alpha in peripheral blood mononuclear cells (PBMCs, EC50 = 8.9 µM). Bufexamac induces hyperacetylation of tubulin (IC50 = 2.9 µM), a major substrate of HDAC6, without increasing acetylation of the class I HDAC substrates H3K5 or H3K9/K14. It also inhibits leukotriene A4 (LTA4) hydrolase and aminopeptidase activity (IC50s = 15.86 and 11.59 µM, respectively) and 5-lipoxygenase (5-LO) activity (IC50 = 27 µM). Bufexamac inhibits the production of leukotriene B4 (LTB4, Cay-20110) in neutrophils (IC50 = 12.91 µM) and reduces fMLP-induced neutrophil migration when used at concentrations of 50 and 100 µM. It also reduces neutrophil levels, as well as protein levels of TNF-alpha and IL-1beta, in bronchoalveolar lavage fluid (BALF) in a mouse model of LPS-induced acute lung injury when administered at a dose of 100 mg/kg.Formal Name: 4-butoxy-N-hydroxy-benzeneacetamide. CAS Number: 2438-72-4. Molecular Formula: C12H17NO3. Formula Weight: 223.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml, Ethanol: 2.5 mg/ml. lambdamax: 229, 278 nm. SMILES: CCCCOC1=CC=C(CC(NO)=O)C=C1. InChi Code: InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14). InChi Key: MXJWRABVEGLYDG-UHFFFAOYSA-N.